Shaping the Future of Biosimilars: Development and Market Access

The Next Wave of Biosimilars: Why Hematology Is a High-Stakes Opportunity

As biosimilar development becomes more competitive and scientifically complex, hematology presents both significant opportunity and meaningful risk. We hope this article provides useful insight into the strategic considerations shaping the next decade of biosimilar development.

Navigating the Changing Biosimilars Market Access Landscape

Evolving regulatory expectations, increasing competition and shifting payer dynamics are redefining how biosimilars achieve market access. As development pathways become more streamlined and advanced modalities emerge, demonstrating value beyond clinical similarity is becoming increasingly important.

This white paper explores how global access frameworks, pricing strategies and stakeholder perceptions are shaping biosimilar uptake, with a focus on regional differences, real-world evidence and competitive positioning.

The Future of Oncology Biosimilars: Considerations for Development Through 2040

As oncology biologics approach patent expiration, biosimilars are poised to expand access to cancer treatments while introducing new complexity across development and regulatory pathways. Evolving guidance, increasing modality diversity and the growing role of real-world evidence are reshaping how biosimilars are brought to market .

This white paper explores how the oncology biosimilars landscape is evolving, with a focus on regulatory change, modality-specific development considerations and post-market strategies to support long-term adoption and success.